Abstract
Background and aims. 5-Fluorouracil (5-FU) is a widely used for colorectal carcinoma. However, the therapeutic effect of 5-FU differs among patients. This difference may be based on the difference in sensitivity of carcinoma cells to 5-FU. The activities of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) are reported to be correlated with cancer cell sensitivity against 5-FU in vitro. We evaluated whether TP and DPD are useful markers of tumor sensitivity for 5-FU in colorectal carcinomas.
Patients and methods. We analyzed the TP and DPD in 189 patients with colorectal carcinoma using an enzyme-linked immunosorbent assay in relation to patients prognosis.
Results. The tumors' mean TP activity was significantly higher than that of noncancerous tissues (100 vs. 47 U/mg protein), but the tumors' mean DPD activity was significantly lower than that of noncancerous tissues (58 vs. 84 U/mg protein). Tumor TP, DPD, and TP/DPD values were not correlated with tumor location or histological types of tumors. Even tumor TP and TP/DPD values in Dukes' stage A tumors were lower than those of other stages; DPD values were not correlated with tumor stages. In 100 patients who underwent intravenous adjuvant 5-FU chemotherapy, prognosis was not correlated with tumor-TP, DPD, or TP/DPD values. Moreover, in 20 patients with synchronous liver metastasis who underwent postoperative 5-FU therapy through the hepatic artery, the survival times of patients was not correlated with tumor-TP, DPD, or TP/DPD values.
Conclusions. These findings indicate that it is questionable to decide the indication of 5-FU chemotherapy according to tumor TP or DPD status in patients with colorectal cancer.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Electronic Publication
Rights and permissions
About this article
Cite this article
Ikeguchi, M., Makino, M. & Kaibara, N. Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis. Langenbecks Arch Surg 387, 240–245 (2002). https://doi.org/10.1007/s00423-002-0313-y
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00423-002-0313-y